# PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

> **NCT02487277** · PHASE2 · TERMINATED · sponsor: **Andrew Ko** · enrollment: 3 (actual)

## Conditions studied

- Adenocarcinoma

## Interventions

- **DRUG:** PEGPH20
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02487277
- **Lead sponsor:** Andrew Ko
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-14
- **Primary completion:** 2018-05-18
- **Final completion:** 2018-05-18
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02487277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02487277, "PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02487277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*